Asterias Biotherapeutics Company Profile (NYSEMKT:AST)

About Asterias Biotherapeutics

Asterias Biotherapeutics logoAsterias Biotherapeutics, Inc. is a biotechnology company. The Company is focused in the field of regenerative medicine. It has three clinical stage product candidates: AST-OPC1 indicated for spinal cord injuries; AST-VAC2 indicated for lung cancer, and AST-VAC1 indicated for prostate cancer and acute myelogenous leukemia. The Company's product development is focused primarily on AST-OPC1 and AST-VAC2. The Company's lead therapeutic program focuses on the development of AST-OPC1 for spinal cord injury. AST-OPC1 product consists of glial progenitor cells, which are cells that become glial cells after injection. AST-VAC1 is an autologous product (using cells that come from the treated patient) consisting of mature antigen-presenting dendritic cells pulsed with ribonucleic acid (RNA) for the protein component of human telomerase (hTERT) and a portion of a lysosomal targeting signal (LAMP).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: NYSEMKT
  • Symbol: AST
  • CUSIP:
Key Metrics:
  • Previous Close: $4.54
  • 50 Day Moving Average: $3.3594
  • 200 Day Moving Average: $3.5492
  • 52-Week Range: $2.30 - $5.75
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.25
  • P/E Growth: 0.0000
  • Market Cap: $205.69M
  • Outstanding Shares: 45,418,000
  • Beta: 1.58
Additional Links:
Companies Related to Asterias Biotherapeutics:

Analyst Ratings

Consensus Ratings for Asterias Biotherapeutics (NYSEMKT:AST) (?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $8.88

Analysts' Ratings History for Asterias Biotherapeutics (NYSEMKT:AST)
Show:
DateFirmActionRatingPrice TargetDetails
9/14/2016FBR & CoReiterated RatingBuyView Rating Details
9/11/2016HC WainwrightReiterated RatingBuy$10.00View Rating Details
5/23/2016Chardan CapitalInitiated CoverageBuy$5.50View Rating Details
5/17/2016Rodman & RenshawReiterated RatingBuy$10.00View Rating Details
8/11/2015MLV & Co.Reiterated RatingBuy$9.00View Rating Details
5/5/2015Lake Street CapitalInitiated CoverageBuy$22.00View Rating Details
(Data available from 9/28/2014 forward)

Earnings

Earnings History for Asterias Biotherapeutics (NYSEMKT:AST)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/15/2016Q216($0.19)($0.12)$1.14 million$1.53 millionViewListenView Earnings Details
5/16/2016Q116($0.14)($0.27)$1.60 millionViewListenView Earnings Details
3/29/2016Q415($0.13)($0.13)$1.07 millionViewListenView Earnings Details
11/9/2015Q315($0.11)($0.06)$1.40 millionViewN/AView Earnings Details
8/10/2015Q215($0.11)($0.10)ViewListenView Earnings Details
5/7/2015($0.13)($0.14)ViewN/AView Earnings Details
3/10/2015($0.13)($0.11)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Asterias Biotherapeutics (NYSEMKT:AST)
Current Year EPS Consensus Estimate: $-0.73 EPS
Next Year EPS Consensus Estimate: $-0.73 EPS

Dividends

Dividend History for Asterias Biotherapeutics (NYSEMKT:AST)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Asterias Biotherapeutics (NYSEMKT:AST)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/9/2016Edward WirthInsiderSell14,760$3.52$51,955.20View SEC Filing  
9/9/2016Katharine E. SpinkCOOSell19,336$3.52$68,062.72View SEC Filing  
6/30/2016Stephen Lahue CarttCEOBuy10,000$2.40$24,000.00View SEC Filing  
6/29/2016Richard T LebuhnDirectorBuy5,000$2.38$11,900.00View SEC Filing  
6/10/2016Stephen Lahue CarttCEOBuy50,000$2.93$146,500.00View SEC Filing  
6/9/2016Alfred D KingsleyDirectorBuy4,000$2.93$11,720.00View SEC Filing  
5/13/2016Natale S RicciardiDirectorBuy14,706$3.39$49,853.34View SEC Filing  
9/15/2015Edward WirthinsiderSell2,880$6.00$17,280.00View SEC Filing  
9/15/2015Katharine E. SpinkCOOSell3,760$6.00$22,560.00View SEC Filing  
6/25/2015Andrew ArnoDirectorBuy5,000$4.32$21,600.00View SEC Filing  
2/9/2015Pedro LichtingerCEOBuy128,205$3.90$499,999.50View SEC Filing  
10/1/2014Scarsdale Equities LlcMajor ShareholderBuy60,000$5.93$355,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Asterias Biotherapeutics (NYSEMKT:AST)
DateHeadline
streetinsider.com logoAsterias Biotherapeutics (AST) Commences Dosing of First Patient in AST-OPC1 Clinical Trial - StreetInsider.com (NYSEMKT:AST)
www.streetinsider.com - September 27 at 8:11 AM
finance.yahoo.com logoAsterias Biotherapeutics Announces Dosing of First Patient in New SCiSTAR Clinical Trial Cohort Testing AST-OPC1 in an Expanded Cervical Spinal Cord Injury Patient Population (NYSEMKT:AST)
finance.yahoo.com - September 27 at 8:11 AM
newsmaker.com.au logo2016 H2 Osteoarthritis Pipeline Market Key Companies Analysis Research (NYSEMKT:AST)
www.newsmaker.com.au - September 22 at 3:36 PM
finance.yahoo.com logoWhy Asterias Biotherapeutics (AST) Could Be Positioned for a Surge? (NYSEMKT:AST)
finance.yahoo.com - September 21 at 4:31 PM
News IconStock Seen Gapping HIgher Before the Start of Trade: Asterias Biotherapeutics, Inc. (:AST) - Post News (NYSEMKT:AST)
www.kentuckypostnews.com - September 20 at 3:35 PM
News IconStocks on Hotspot- Asterias Biotherapeutics (NYSE:AST), Scientific Games (NASDAQ:SGMS), Infoblox (NYSE:BLOX) - Seneca Globe (NYSEMKT:AST)
www.senecaglobe.com - September 20 at 3:35 PM
News IconBiotech Stocks To Put On Your Watch List: Novavax, Inc. (NASDAQ:NVAX), Asterias Biotherapeutics, Inc. (NYSEMKT ... - The Voice Registrar (NYSEMKT:AST)
voiceregistrar.com - September 20 at 3:35 PM
finance.yahoo.com logoThis Historic Medical Breakthrough Is a Game Changer for Biotech (NYSEMKT:AST)
finance.yahoo.com - September 20 at 9:32 AM
4-traders.com logoASTERIAS BIOTHERAPEUTICS, INC. : Material Modification to Rights of Security Holders, Financial Statements and Exhibits (form 8-K) (NYSEMKT:AST)
www.4-traders.com - September 19 at 8:24 AM
biz.yahoo.com logoASTERIAS BIOTHERAPEUTICS, INC. Files SEC form 8-K, Material Modification to Rights of Security Holders, Financial Sta (NYSEMKT:AST)
biz.yahoo.com - September 19 at 8:24 AM
businesswire.com logoBioTime Affiliate, Asterias Biotherapeutics, Announced Positive Interim Efficacy Data From Trial in Patients With ... - Business Wire (press release) (NYSEMKT:AST)
www.businesswire.com - September 15 at 8:44 PM
News IconBiotech news that matter for investors: Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), Asterias Biotherapeutics, Inc ... - The Voice Registrar (NYSEMKT:AST)
voiceregistrar.com - September 15 at 12:30 PM
finance.yahoo.com logoAsterias Biotherapeutics (AST) Catches Eye: Stock Jumps 6% (NYSEMKT:AST)
finance.yahoo.com - September 15 at 12:30 PM
capitalcube.com logoETF’s with exposure to Asterias Biotherapeutics, Inc. : September 15, 2016 (NYSEMKT:AST)
www.capitalcube.com - September 15 at 12:30 PM
News IconStock Gapping Higher Before the Bell: Asterias Biotherapeutics, Inc. (:AST) - Post News (NYSEMKT:AST)
www.kentuckypostnews.com - September 14 at 3:37 PM
News IconShares Climbing Higher Session: Asterias Biotherapeutics, Inc. (:AST) - Post News (NYSEMKT:AST)
www.kentuckypostnews.com - September 14 at 3:37 PM
finance.yahoo.com logoWill Asterias Biotherapeutics (AST) Continue to Surge Higher? (NYSEMKT:AST)
finance.yahoo.com - September 14 at 3:37 PM
finance.yahoo.com logoAsterias stem cell therapy shows promise in spinal cord paralysis -U.S. study (NYSEMKT:AST)
finance.yahoo.com - September 14 at 7:31 AM
finance.yahoo.com logoAsterias Biotherapeutics Announces Positive Efficacy Data in Patients with Complete Cervical Spinal Cord Injuries Treated with AST-OPC1 (NYSEMKT:AST)
finance.yahoo.com - September 14 at 7:31 AM
News IconBiotech Stocks Worth a Closer Look: Lexicon Pharmaceuticals, Inc ... - The Voice Registrar (NYSEMKT:AST)
voiceregistrar.com - September 13 at 8:26 AM
finance.yahoo.com logoAsterias Biotherapeutics Announces AST-OPC1 SCiSTAR Study Investigator Charles Y. Liu, MD, PhD, and Director, USC Neurorestoration Center, to Discuss Interim Data on Conference Call on September 14, 2016 (NYSEMKT:AST)
finance.yahoo.com - September 13 at 8:26 AM
bizjournals.com logoIn paralyzed man's 'promising' recovery, new hope, hype for stem cells (NYSEMKT:AST)
feeds.bizjournals.com - September 12 at 6:16 PM
finance.yahoo.com logoAsterias Biotherapeutics to Present at Rodman & Renshaw Annual Global Investment Conference Today, September … (NYSEMKT:AST)
finance.yahoo.com - September 12 at 3:35 PM
zacks.com logoAsterias Biotherapeutics (AST) Soars: Stock Rises by 10.9% (NYSEMKT:AST)
www.zacks.com - September 12 at 8:25 AM
News IconShares Gapping Up Pre-Bell: Asterias Biotherapeutics, Inc. (:AST ... - Post News (NYSEMKT:AST)
www.kentuckypostnews.com - September 9 at 3:33 PM
News IconBullish Movers Gaining Investors Attention: Asterias Biotherapeutics, Inc. (NYSE:AST), Palo Alto Networks, Inc ... - Street Wise Report (press release) (blog) (NYSEMKT:AST)
streetwisereport.com - September 9 at 3:33 PM
News IconBiotech Stocks To Put On Your Watch List: Asterias Biotherapeutics, Inc. (NYSEMKT:AST), Repros Therapeutics Inc ... - The Voice Registrar (NYSEMKT:AST)
voiceregistrar.com - September 9 at 3:33 PM
News IconStock Showing Gains in Afternoon Trading: Asterias Biotherapeutics, Inc. (:AST) - National Daily Press (NYSEMKT:AST)
www.nationaldailypress.com - September 9 at 8:24 AM
News IconShares Higher in Today's Session: Asterias Biotherapeutics, Inc. (:AST) - Post News (NYSEMKT:AST)
www.kentuckypostnews.com - September 9 at 8:24 AM
prnewswire.com logoAsterias Biotherapeutics Announces Interim Efficacy Data from ... - PR Newswire (press release) (NYSEMKT:AST)
www.prnewswire.com - September 7 at 3:36 PM
finance.yahoo.com logoAsterias Biotherapeutics Announces Interim Efficacy Data from SCiStar Clinical Trial of AST-OPC1 in Complete … (NYSEMKT:AST)
finance.yahoo.com - September 7 at 12:25 PM
News IconOTC Investors Supremely Interested in Shares of Asterias Biotherapeutics, Inc. (:AST) - Duncan Research (NYSEMKT:AST)
www.duncanindependent.com - September 6 at 8:46 PM
publicnow.com logoСurrent report No 19/2016 (NYSEMKT:AST)
www.publicnow.com - September 6 at 3:42 PM
News IconA Second Look at Shares of Asterias Biotherapeutics, Inc. (:AST) - Duncan Research (NYSEMKT:AST)
www.duncanindependent.com - September 3 at 8:27 AM
finance.yahoo.com logoAsterias Biotherapeutics Receives Safety Clearance to Begin Administering the Highest Dose of AST-OPC1 in the SCiStar Phase 1/2a Clinical Trial in Cervical Spinal Cord Injury Patients (NYSEMKT:AST)
finance.yahoo.com - September 3 at 8:27 AM
News IconUnder the Magnifying Glass: A Closer Look at Asterias Biotherapeutics, Inc. (:AST) - Duncan Research (NYSEMKT:AST)
www.duncanindependent.com - September 1 at 12:03 PM
News IconTaking a Serious Look at Asterias Biotherapeutics, Inc. (:AST) - Duncan Research (NYSEMKT:AST)
www.duncanindependent.com - August 31 at 3:36 PM
prnewswire.com logoAsterias Biotherapeutics Receives Safety Clearance to Begin Administering the Highest Dose of AST-OPC1 in the ... - PR Newswire (press release) (NYSEMKT:AST)
www.prnewswire.com - August 31 at 8:24 AM
News IconZeroing Our Focus on Asterias Biotherapeutics, Inc. (:AST) - Duncan Research (NYSEMKT:AST)
www.duncanindependent.com - August 30 at 3:35 PM
kcregister.com logoAsterias Biotherapeutics, Inc. (NYSE:AST) edged 1.10%: Provectus Biopharmaceuticals, Inc. (NYSE:PVCT), Citigroup ... - KC Register (NYSEMKT:AST)
www.kcregister.com - August 29 at 8:22 AM
News IconOTC Investors Keen on Shares of Asterias Biotherapeutics, Inc. (:AST) - Duncan Research (NYSEMKT:AST)
www.duncanindependent.com - August 26 at 3:35 PM
News IconPenny Stock Under the Microscope: Asterias Biotherapeutics, Inc. (:AST) - Duncan Research (NYSEMKT:AST)
www.duncanindependent.com - August 26 at 11:45 AM
publicnow.com logoFairfax to become a substantial shareholder in Astarta (NYSEMKT:AST)
www.publicnow.com - August 26 at 11:45 AM
publicnow.com logoASTARTA starts sugar production campaign (NYSEMKT:AST)
www.publicnow.com - August 26 at 11:45 AM
publicnow.com logoСurrent report No 18/2016 (NYSEMKT:AST)
www.publicnow.com - August 25 at 3:40 PM
News IconLooking Closer at Stocks of Asterias Biotherapeutics, Inc. (:AST) - Duncan Research (NYSEMKT:AST)
www.duncanindependent.com - August 25 at 8:26 AM
capitalcube.com logoETF’s with exposure to Asterias Biotherapeutics, Inc. : August 24, 2016 (NYSEMKT:AST)
www.capitalcube.com - August 24 at 11:51 AM
News IconMagnifying Stocks of Asterias Biotherapeutics, Inc. (:AST) - Duncan Research (NYSEMKT:AST)
www.duncanindependent.com - August 23 at 8:52 PM
finance.yahoo.com logoASTERIAS BIOTHERAPEUTICS, INC. Financials (NYSEMKT:AST)
finance.yahoo.com - August 23 at 3:38 PM
News IconLet's Take a Closer Look at Asterias Biotherapeutics, Inc. (:AST) - Duncan Research (NYSEMKT:AST)
www.duncanindependent.com - August 22 at 8:43 PM

Social


Last Updated on 9/28/2016 by MarketBeat.com Staff